Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo. Issue 1 (17th May 2016)

• Record Type: Journal Article
• Authors: Stanton, Sasha E.; Eary, Janet F.; Marzbani, Edmond A.; Mankoff, David; Salazar, Lupe G.; Higgins, Doreen; Childs, Jennifer; Reichow, Jessica; Dang, Yushe; Disis, Mary L.
• Is Part Of: Journal for immunotherapy of cancer. Volume 4:Issue 1(2016)
• Publication Date: 2016-05-17
• Subjects: Adoptive T-cell therapy -- HER2 -- breast cancer -- Indium-111 labeled -- FDG -- PET-CT -- SPECT; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1186/s40425-016-0131-3
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: The ability of T-cells to traffic to and penetrate tumors impacts the clinical efficacy of T-cell therapy therefore methods to track transferred T-cells in vivo are needed. In this preliminary report, we evaluated the use of concurrent SPECT/PET-CT imaging to monitor the egress of HER-2/neu specific T-cells in a breast cancer patient with extensive bone-only metastatic disease. Findings: Indium (In-111) labeled T-cells demonstrated similar or greater viability than unlabeled T-cells at either a low or high dose of In-111 over a 24-h incubation period in vitro. The function of labeled or unlabeled T-cells was not significantly different ( p > 0.05) at either dose. T-cells trafficked to all sites of metastatic disease and infiltrated the tumor as assessed by SPECT imaging. In-111 uptake at 24 h after infusion varied from 3.8 (right proximal humerus) to 6.3 (right sacrum) background corrected counts per pixel and remained elevated at 48 h. Concurrent PET-CT imaging demonstrated a fluorodeoxyglucose flare, measured by increase in tumor site uptake as high as 32 % and at most sites of disease at 48 h. This flare was associated with focal pain after T-cell infusion at metastatic sites. The patient had stable disease for 18 months after completion of T-cell therapy. Conclusion: Concurrent SPECT/PET-CT imaging, over a 48-h period after T-cell infusion, provided evidence of T-cell homing to all disease sites as well as a tumor metabolism flare response. This technique may be useful for monitoring T-cell trafficking after autologous as well as chimeric antigen receptor T-cell infusion. Trial Registraion: Trial registered at ClinicalTrials.gov registration number NCT00791037, registered 13 November 2008.